KX-826 Shows Promising Results in Women with Pattern Hair Loss: What You Need to Know
Introduction
Kintor Pharmaceuticals has announced topline results from its Phase II clinical trial of KX-826 in women with androgenetic alopecia (AGA), also known as female pattern hair loss. These early findings confirm what many in the dermatology world hoped: KX-826 isn’t just effective for men — it could be a powerful new option for women too.
About the Trial
- Type: Multicenter, randomized, double-blind, placebo-controlled
- Participants: 180 women in China with moderate AGA
- Treatment Period: 24 weeks
- Dosing: KX-826 applied topically once daily
Topline Results
✅ Primary Endpoint Met:
-
The 0.5% KX-826 group showed statistically significant improvement in non-vellus target area hair count compared to placebo (p = 0.0146)
✅ Secondary Endpoints Positive:
- Multiple secondary metrics also showed clear improvement with 0.5% KX-826 vs. placebo
- Safety profile remained favorable, with no serious adverse events reported
What This Means
These results mark an important milestone in expanding safe, effective, and non-hormonal treatment options for women with AGA. Most existing treatments for female hair loss are limited in efficacy or carry systemic side effects — KX-826 could soon offer a new path forward.
How KX-826 Works
KX-826 (Pyrilutamide) is a topical androgen receptor antagonist. It’s designed to block the effects of DHT at the scalp without altering hormone levels throughout the body. For women concerned about hormonal side effects or oral medications, this could be a safer, smarter solution.
Regenvia’s Role
At Regenvia, we’re proud to partner with Koshine Biomedica, a consumer brand under Kintor Pharmaceuticals, to bring KX-826-based formulas to consumers today — including options designed for women. Our mist formulations deliver KX-826 directly to the scalp in a clean, lightweight format that fits into any routine.
Click here to learn more from Kintor Pharmaceutical's announcement.